Compare Stocks: DYN, BMRN, MDGL, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$58.51 +1.8%	$60.62	$49.26 ▼ $70.98	$11.33B	0.22	2.53 million shs	2.27 million shs
DYN Dyne Therapeutics	$16.69 -2.1%	$18.53	$14.00 ▼ $27.31	$3.12B	1.12	2.94 million shs	1.45 million shs
KRYS Krystal Biotech	$332.29 +2.4%	$337.46	$184.02 ▼ $382.54	$9.84B	0.5	269,648 shs	330,046 shs
MDGL Madrigal Pharmaceuticals	$430.36 -0.3%	$498.66	$399.00 ▼ $615.00	$9.94B	-1.04	303,055 shs	251,523 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	0.00%	+4.58%	+0.12%	-2.52%	+12.82%
DYN Dyne Therapeutics	0.00%	+6.85%	+5.50%	-33.72%	-29.37%
KRYS Krystal Biotech	0.00%	+6.67%	+2.15%	-2.59%	+79.57%
MDGL Madrigal Pharmaceuticals	0.00%	-0.89%	-13.88%	-7.91%	+2.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$58.51 +1.8%	$60.62	$49.26 ▼ $70.98	$11.33B	0.22	2.53 million shs	2.27 million shs
DYN Dyne Therapeutics	$16.69 -2.1%	$18.53	$14.00 ▼ $27.31	$3.12B	1.12	2.94 million shs	1.45 million shs
KRYS Krystal Biotech	$332.29 +2.4%	$337.46	$184.02 ▼ $382.54	$9.84B	0.5	269,648 shs	330,046 shs
MDGL Madrigal Pharmaceuticals	$430.36 -0.3%	$498.66	$399.00 ▼ $615.00	$9.94B	-1.04	303,055 shs	251,523 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	0.00%	+4.58%	+0.12%	-2.52%	+12.82%
DYN Dyne Therapeutics	0.00%	+6.85%	+5.50%	-33.72%	-29.37%
KRYS Krystal Biotech	0.00%	+6.67%	+2.15%	-2.59%	+79.57%
MDGL Madrigal Pharmaceuticals	0.00%	-0.89%	-13.88%	-7.91%	+2.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.80	Moderate Buy	$88.38	51.04% Upside
DYN Dyne Therapeutics	2.69	Moderate Buy	$31.29	87.45% Upside
KRYS Krystal Biotech	2.93	Moderate Buy	$377.20	13.52% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.20	62.47% Upside

Current Analyst Ratings Breakdown

Latest DYN, BMRN, MDGL, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Market Perform	$40.00 ➝ $15.00
10/23/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/23/2026	KRYS Krystal Biotech	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/21/2026	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$124.00 ➝ $122.00
10/20/2026	BMRN BioMarin Pharmaceutical	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$86.00 ➝ $87.00
10/20/2026	BMRN BioMarin Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$86.00
10/15/2026	DYN Dyne Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	MDGL Madrigal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$114.00 ➝ $88.00
10/15/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$361.00

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.52	$2.85 per share	20.51	$31.68 per share	1.85
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
KRYS Krystal Biotech	$389.13M	25.28	$7.29 per share	45.58	$42.06 per share	7.90
MDGL Madrigal Pharmaceuticals	$958.40M	10.37	N/A	N/A	$26.54 per share	16.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	158.14	11.02	0.64	2.14%	5.32%	3.69%	11/2/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	41.64	37.85	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	81.20	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)

Latest DYN, BMRN, MDGL, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	DYN Dyne Therapeutics	-$0.9073	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8629	N/A	N/A	N/A	$404.17 million	N/A
11/2/2026	Q3 2026	BMRN BioMarin Pharmaceutical	-$0.0833	N/A	N/A	N/A	$1.02 billion	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.79	N/A	N/A	N/A	$125.77 million	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
DYN Dyne Therapeutics	0.28	12.02	12.02
KRYS Krystal Biotech	N/A	8.32	7.96
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
DYN Dyne Therapeutics	96.68%
KRYS Krystal Biotech	86.29%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
DYN Dyne Therapeutics	9.46%
KRYS Krystal Biotech	13.10%
MDGL Madrigal Pharmaceuticals	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable

DYN, BMRN, MDGL, and KRYS Headlines

Recent News About These Companies

Canaccord Genuity Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

October 31 at 1:42 PM | theglobeandmail.com

Madrigal Pharmaceuticals stock trades at 384.25 euros Friday

October 30 at 10:30 PM | ad-hoc-news.deA

Madrigal Pharmaceuticals Inc.

October 29 at 8:08 PM | marketwatch.com

Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know

October 27, 2026 | zacks.com

Madrigal Pharmaceuticals (MDGL) Expected to Announce Earnings on Tuesday

October 27, 2026 | marketbeat.com

Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH

October 27, 2026 | globenewswire.com

Critical Contrast: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Incyte (NASDAQ:INCY)

October 25, 2026 | americanbankingnews.com

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

October 20, 2026 | seekingalpha.com

UBS raises target to USD 735 for Madrigal Pharmaceuticals stock

October 20, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026

October 20, 2026 | globenewswire.com

Madrigal Pharmaceuticals, Inc. $MDGL Stock Sold by Assenagon Asset Management S.A.

October 20, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Has Average Target Price of $699.20 According to Analysts

October 20, 2026 | marketbeat.com

BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral Rating

October 19, 2026 | marketscreener.comM

UBS raises target to USD 735.00 for Madrigal Pharmaceuticals stock

October 17, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - October 15, 2026

October 16, 2026 | biospace.comB

UBS lifts target for Madrigal Pharmaceuticals stock to USD 735.00

October 15, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

October 15, 2026 | globenewswire.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Newly Acquired by Sivik Global Healthcare LLC

October 13, 2026 | marketbeat.com

Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)

October 10, 2026 | theglobeandmail.com

Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run

October 8, 2026 | uk.finance.yahoo.com

Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus

October 8, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DYN, BMRN, MDGL, and KRYS Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$58.51 +1.02 (+1.77%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$58.54 +0.02 (+0.04%)

As of 10/30/2026 07:30 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Dyne Therapeutics NASDAQ:DYN

$16.69 -0.35 (-2.05%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$16.69 0.00 (0.00%)

As of 10/30/2026 07:30 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Krystal Biotech NASDAQ:KRYS

$332.29 +7.74 (+2.38%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$332.33 +0.04 (+0.01%)

As of 10/30/2026 07:54 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Madrigal Pharmaceuticals NASDAQ:MDGL

$430.36 -1.34 (-0.31%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$434.50 +4.14 (+0.96%)

As of 10/30/2026 07:47 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, BMRN, MDGL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, BMRN, MDGL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, BMRN, MDGL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, BMRN, MDGL, and KRYS Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Dyne Therapeutics NASDAQ:DYN

Krystal Biotech NASDAQ:KRYS

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, BMRN, MDGL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, BMRN, MDGL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, BMRN, MDGL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, BMRN, MDGL, and KRYS Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Dyne Therapeutics NASDAQ:DYN

Krystal Biotech NASDAQ:KRYS

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools